丙型肝炎病毒的当前管理：肝移植围手术期患者的治疗方案
Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients.
作者信息
Saxena Varun, Terrault Norah
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
出版信息
Clin Liver Dis. 2015 Nov;19(4):669-88, vi. doi: 10.1016/j.cld.2015.06.007. Epub 2015 Jul 26.
Abstract
Chronic hepatitis C virus (HCV) infection currently remains the leading indication for liver transplant in the United States. However, recurrent HCV infection after transplant is universal in those who enter transplant with viremia resulting in reduced posttransplant graft and patient survival rates, caused in large part by progressive recurrent HCV disease. Therefore, successful treatment of HCV in the peri-transplant period, either before or after transplant, is paramount in ensuring improved posttransplant outcomes. This article reviews the experience to date treating HCV in wait-listed patients and liver transplant recipients and the unique challenges encountered when treating this population.
摘要
目前，慢性丙型肝炎病毒（HCV）感染仍是美国肝移植的主要指征。然而，移植前存在病毒血症的患者移植后普遍会出现HCV复发感染，这导致移植后移植物和患者生存率降低，很大程度上是由进行性复发性HCV疾病所致。因此，在移植围手术期（移植前或移植后）成功治疗HCV对于确保改善移植后结局至关重要。本文回顾了迄今为止在等待移植患者和肝移植受者中治疗HCV的经验，以及治疗这一人群时遇到的独特挑战。
相似文献
1
Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients.丙型肝炎病毒的当前管理：肝移植围手术期患者的治疗方案
Clin Liver Dis. 2015 Nov;19(4):669-88, vi. doi: 10.1016/j.cld.2015.06.007. Epub 2015 Jul 26.
2
Impact of new treatment options for hepatitis C virus infection in liver transplantation.丙型肝炎病毒感染的新治疗方案对肝移植的影响。
World J Gastroenterol. 2015 Oct 14;21(38):10760-75. doi: 10.3748/wjg.v21.i38.10760.
3
Regimens for Cirrhotic Patients.肝硬化患者的治疗方案。
Clin Liver Dis. 2015 Nov;19(4):657-67, vi. doi: 10.1016/j.cld.2015.06.006. Epub 2015 Jul 26.
4
Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.用于治疗肝移植候选者或接受者丙型肝炎病毒的无干扰素方案。
World J Gastroenterol. 2015 Aug 28;21(32):9526-33. doi: 10.3748/wjg.v21.i32.9526.
5
Regimens for the Hepatitis C Treatment-Naive Patient.初治丙型肝炎患者的治疗方案。
Clin Liver Dis. 2015 Nov;19(4):619-27, v. doi: 10.1016/j.cld.2015.06.003. Epub 2015 Aug 7.
6
Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in.肝移植患者丙型肝炎的治疗：干扰素出局，直接抗病毒药物联合方案登场。
Liver Transpl. 2015 Apr;21(4):423-34. doi: 10.1002/lt.24080.
7
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.肝移植前接受来迪派韦/索磷布韦联合利巴韦林治疗的丙型肝炎患者肝移植后病毒学应答的持久性
Ann Hepatol. 2017 May-Jun;16(3):375-381. doi: 10.5604/16652681.1235480.
8
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].[慢性丙型肝炎治疗的新时代——新型直接作用抗病毒药物]
Orv Hetil. 2015 May 24;156(21):841-8. doi: 10.1556/650.2015.30177.
9
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.基于无干扰素索磷布韦的移植后丙型肝炎复发治疗——瑞典的真实生活经验
Scand J Gastroenterol. 2017 May;52(5):585-588. doi: 10.1080/00365521.2017.1283439. Epub 2017 Feb 13.
10
Management of recurrent hepatitis C virus after liver transplantation.肝移植后复发性丙型肝炎病毒的管理。
World J Gastroenterol. 2014 Nov 28;20(44):16409-17. doi: 10.3748/wjg.v20.i44.16409.
引用本文的文献
1
Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection.评估持续病毒学应答作为丙型肝炎病毒感染长期结局的相关替代终点。
Clin Infect Dis. 2021 Mar 1;72(5):780-786. doi: 10.1093/cid/ciaa144.
2
Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients.丙型肝炎治疗对肝移植患者肾功能的影响。
J Clin Transl Hepatol. 2018 Dec 28;6(4):391-395. doi: 10.14218/JCTH.2018.00026. Epub 2018 Jul 11.
3
Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States.美国丙型肝炎患者在等待肝移植时死亡率和疾病严重程度降低。
Liver Transpl. 2018 Jun;24(6):735-743. doi: 10.1002/lt.24973. Epub 2018 Mar 25.
4
Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.直接抗病毒疗法在既往肝移植后复发丙型肝炎病毒感染的难治性患者中的疗效和安全性：一项真实世界队列研究
Drug Des Devel Ther. 2017 Jul 12;11:2131-2138. doi: 10.2147/DDDT.S139837. eCollection 2017.
5
Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?丙型肝炎潜在肝移植受者：应在移植前还是移植后进行治疗？
J Clin Exp Hepatol. 2017 Mar;7(1):42-54. doi: 10.1016/j.jceh.2017.01.116. Epub 2017 Feb 6.
6
Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.肝移植等待名单上丙型肝炎患者的最佳治疗时机。
Hepatology. 2017 Mar;65(3):777-788. doi: 10.1002/hep.28926. Epub 2017 Jan 6.
7
Treatment of Hepatitis C Infection in Renal Transplant Recipients: The Long Wait Is Over.肾移植受者丙型肝炎感染的治疗：漫长等待结束了。
Am J Transplant. 2016 May;16(5):1345-7. doi: 10.1111/ajt.13697. Epub 2016 Mar 15.
本文引用的文献
1
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.索磷布韦和达卡他韦治疗肝移植后纤维性胆汁淤积性丙型肝炎患者的疗效。
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1993-2001.e1-2. doi: 10.1016/j.cgh.2015.05.030. Epub 2015 Jun 1.
2
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.西米普明/索非布韦治疗代偿期和失代偿期丙型肝炎肝硬化患者的安全性和有效性。
Hepatology. 2015 Sep;62(3):715-25. doi: 10.1002/hep.27922. Epub 2015 Jul 30.
3
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.来迪派韦索磷布韦与利巴韦林联合治疗晚期肝病患者的 HCV 感染。
Gastroenterology. 2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15.
4
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.索磷布韦与利迪帕韦治疗基因 1 型丙型肝炎病毒感染合并代偿性肝硬化患者的安全性和疗效综合分析。
Hepatology. 2015 Jul;62(1):79-86. doi: 10.1002/hep.27826. Epub 2015 May 9.
5
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.奥比他韦联合帕立瑞韦联合利托那韦加或不加利巴韦林治疗初治和经治的基因 4 型慢性丙型肝炎病毒感染患者（PEARL-I）：一项随机、开放标签试验。
Lancet. 2015 Jun 20;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3. Epub 2015 Mar 31.
6
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.多中心使用simeprevir 和 sofosbuvir 联合或不联合利巴韦林治疗肝移植后丙型肝炎基因型 1 的经验。
Hepatology. 2015 Jun;61(6):1880-6. doi: 10.1002/hep.27770. Epub 2015 Apr 27.
7
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.基于替拉普韦和博赛匹韦的三联疗法用于治疗晚期复发性疾病的肝移植受者的丙型肝炎：一项多中心研究。
Transplantation. 2015 Aug;99(8):1644-51. doi: 10.1097/TP.0000000000000629.
8
Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?丙型肝炎直接抗病毒药物与晚期肝硬化患者的肝失代偿：罪魁祸首还是无辜旁观者？
Dig Dis Sci. 2015 Apr;60(4):806-9. doi: 10.1007/s10620-015-3535-x.
9
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.索磷布韦同情用药项目用于肝移植后严重复发性丙型肝炎患者。
Hepatology. 2015 May;61(5):1485-94. doi: 10.1002/hep.27681. Epub 2015 Mar 20.
10
An interferon-free antiviral regimen for HCV after liver transplantation.肝移植后 HCV 的无干扰素抗病毒治疗方案。
N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11.
Zotero 插件